Canaccord Genuity analyst William Plovanic maintained a Buy rating on TransMedics Group yesterday and set a price target of $152.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
William Plovanic has given his Buy rating due to a combination of factors tied to TransMedics’ expanding competitive position and product strategy. He views the new CHOPS platform as a pivotal addition that broadens the company from a niche warm-perfusion player into a full‑suite provider offering both advanced machine perfusion and controlled cold storage, aligning with surgeons’ varying preferences and clinical practices.
He also emphasizes that, regardless of how forthcoming randomized ENHANCE and DENOVO trial results ultimately read out, TransMedics is now structurally positioned to benefit in heart and lung transplantation. Either OCS helps drive a shift toward more efficient daytime procedures, or CHOPS enables the firm to capture standard donor-after-brain-death cases and compete head‑to‑head with incumbent cold‑storage systems, supporting his unchanged $152 price target and Buy rating.
In another report released on April 24, TD Cowen also reiterated a Buy rating on the stock with a $190.00 price target.
TMDX’s price has also changed moderately for the past six months – from $132.450 to $108.120, which is a -18.37% drop .